What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The PA5108 Ocular Implant high dose is supplied preloaded into the needle of a single use administration device ready for use.”In the company’s words, NCT06964191 on ClinicalTrials.gov
- Tested for
- Glaucoma, Open-Angle, Ocular Hypertension
- Main trialPhase 2
- “The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.”In the company’s words, NCT06964191 on ClinicalTrials.gov
Other drugs for Glaucoma, Open-Angle
- Bimatoprost ophthalmic 0.01% YSBPYS Life Science Co., Ltd. · Phase 3
- HUC3-637Huons Co., Ltd. · Phase 3
- Gen 2 Travoprost Intracameral ImplantGlaukos Corporation · Phase 3
- Product DNN.31.19.026Ache Laboratorios Farmaceuticos S.A. · Phase 3
- Citicoline eye drops 2%Omikron Italia S.r.l. · Phase 3
- Bimatoprost 0.01% OphthalmicAmneal Pharmaceuticals, LLC · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 15 Nov 2026 | Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | |
| Phase 1Completed | 13 May 2025 | Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026